Author

G. Wirnsberger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

J. M. Penninger· 3 shared A. Hladik· 2 shared A. Mirazimi· 2 shared C. Oostenbrink· 2 shared J. W. Perthold· 2 shared L. Pimenov· 2 shared R. Gawish· 2 shared S. Knapp· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

J. M. Penninger

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Development of a novel, pan-variant aerosol intervention for COVID-19

R. H. Shoemaker, R. A. Panettieri, S. K. Libutti, H. S. Hochster, N. R. Watts, P. T. Wingfield, P. M. Starkl, L. Pimenov, R. Gawish, A. Hladik, S. Knapp, D. Boring, J. M. White, Q. Lawrence, J. Boone, , G. Wirnsberger

This paper reports preclinical development and evaluation of aerosolized soluble recombinant human ACE2 (APN01) as a COVID-19 intervention.

bioRxiv · Sep 14, 2021 · PreprintPharmacology & Toxicology

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

T. Capraz, N. F. Kienzl, E. Laurent, J. W. Perthold, E. Foederl-Hoebenreich, C. Gruenwald-Gruber, D. Maresch, V. Monteil, J. Niederhoefer, G. Wirnsberger, A. Mirazimi, K. Zatloukal, L. Mach, J. M. Penninger, C. Oostenbrink, J. Stadlmann

This study engineers ACE2 glycosylation to enhance its binding to SARS-CoV-2 Spike protein, resulting in a more potent decoy receptor for COVID-19 treatment.

bioRxiv · Aug 31, 2021Biochemistry

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

R. Gawish, P. Starkl, L. Pimenov, A. Hladik, K. Lakovits, F. Oberndorfer, S. J. F. Cronin, A. Ohradanova-Repic, G. Wirnsberger, B. Agerer, L. Endler, T. Capraz, J. W. Perthold, A. Hagelkruys, N. Montserrat, , S. Knapp

This paper develops a mouse-adapted SARS-CoV-2 strain, maVie16, to model COVID-19 in mice, showing that ACE2 is critical for disease and that blocking TNF/IFNγ reduces immunopathology.

bioRxiv · Aug 9, 2021Immunology